To compare the lipidomic profile in patients with HIV-1 with viral suppression changing efavirenz + emtricitabine + tenofovir (Atripla) to rilpivirine + emtricitabine + tenofovir (Eviplera®) versus a group of patients that continue with Atripla®.

Inclusion Criteria:

• Patients aged 18 years or above
• Patients infected with HIV-1
• Patients treated with Atripla at least the last 6 months.
• Patients with virologic suppression (HIV RNA <50 copies / ml) for at least the last 6 months.
• Women of childbearing potential must use contraception double barrier.
• Voluntary signature of informed consent

Exclusion Criteria:

• Any acute or chronic (besides chronic HIV-1) disease that could interfere with the analysis of lipidomic
• Women pregnant or lactating
• Abuse of alcohol or other drugs
• Body Mass Index (BMI)> 25
• Use of drugs that may affect lipid metabolism (lipid-lowering drugs, steroids ...)
• Patients unable to understand the study protocol or any other condition that in the investigator's opinion could jeopardize compliance with the protocol
• History or presence of allergy to any of the study drugs or their components